To our knowledge, this is the first study to link TGFβ/SMAD4 regulated genes to clinical information on ovarian cancer patient survival and identify potential gene signatures for prognosis in ovarian cancer. This evidence concerns the gene SMAD4 and ovarian carcinoma.